These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 21106982)

  • 1. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78.
    Roué G; Pérez-Galán P; Mozos A; López-Guerra M; Xargay-Torrent S; Rosich L; Saborit-Villarroya I; Normant E; Campo E; Colomer D
    Blood; 2011 Jan; 117(4):1270-9. PubMed ID: 21106982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.
    Buontempo F; Orsini E; Lonetti A; Cappellini A; Chiarini F; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; Bertacchini J; Neri LM; McCubrey JA; Martelli AM
    Oncotarget; 2016 Jan; 7(2):1323-40. PubMed ID: 26593250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells.
    Rao R; Nalluri S; Fiskus W; Savoie A; Buckley KM; Ha K; Balusu R; Joshi A; Coothankandaswamy V; Tao J; Sotomayor E; Atadja P; Bhalla KN
    Clin Cancer Res; 2010 Oct; 16(19):4742-54. PubMed ID: 20647473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma.
    Jin L; Tabe Y; Kimura S; Zhou Y; Kuroda J; Asou H; Inaba T; Konopleva M; Andreeff M; Miida T
    Br J Cancer; 2011 Jan; 104(1):91-100. PubMed ID: 21139584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma.
    Moros A; Rodríguez V; Saborit-Villarroya I; Montraveta A; Balsas P; Sandy P; Martínez A; Wiestner A; Normant E; Campo E; Pérez-Galán P; Colomer D; Roué G
    Leukemia; 2014 Oct; 28(10):2049-59. PubMed ID: 24721791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large b-cell lymphoma.
    Mozos A; Roué G; López-Guillermo A; Jares P; Campo E; Colomer D; Martinez A
    Am J Pathol; 2011 Nov; 179(5):2601-10. PubMed ID: 21907693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.
    Lamoureux F; Thomas C; Yin MJ; Fazli L; Zoubeidi A; Gleave ME
    Eur Urol; 2014 Jul; 66(1):145-55. PubMed ID: 24411988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma.
    Weniger MA; Rizzatti EG; Pérez-Galán P; Liu D; Wang Q; Munson PJ; Raghavachari N; White T; Tweito MM; Dunleavy K; Ye Y; Wilson WH; Wiestner A
    Clin Cancer Res; 2011 Aug; 17(15):5101-12. PubMed ID: 21712452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer.
    Song D; Chaerkady R; Tan AC; García-García E; Nalli A; Suárez-Gauthier A; López-Ríos F; Zhang XF; Solomon A; Tong J; Read M; Fritz C; Jimeno A; Pandey A; Hidalgo M
    Mol Cancer Ther; 2008 Oct; 7(10):3275-84. PubMed ID: 18852131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRAP1 role in endoplasmic reticulum stress protection favors resistance to anthracyclins in breast carcinoma cells.
    Sisinni L; Maddalena F; Lettini G; Condelli V; Matassa DS; Esposito F; Landriscina M
    Int J Oncol; 2014 Feb; 44(2):573-82. PubMed ID: 24297638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PRDM1 is required for mantle cell lymphoma response to bortezomib.
    Desai S; Maurin M; Smith MA; Bolick SC; Dessureault S; Tao J; Sotomayor E; Wright KL
    Mol Cancer Res; 2010 Jun; 8(6):907-18. PubMed ID: 20530581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.
    Yasui H; Hideshima T; Ikeda H; Jin J; Ocio EM; Kiziltepe T; Okawa Y; Vallet S; Podar K; Ishitsuka K; Richardson PG; Pargellis C; Moss N; Raje N; Anderson KC
    Br J Haematol; 2007 Feb; 136(3):414-23. PubMed ID: 17173546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak.
    Pérez-Galán P; Roué G; Villamor N; Campo E; Colomer D
    Blood; 2007 May; 109(10):4441-9. PubMed ID: 17227835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9.
    Georgakis GV; Li Y; Younes A
    Br J Haematol; 2006 Oct; 135(1):68-71. PubMed ID: 16925576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.
    Alinari L; White VL; Earl CT; Ryan TP; Johnston JS; Dalton JT; Ferketich AK; Lai R; Lucas DM; Porcu P; Blum KA; Byrd JC; Baiocchi RA
    MAbs; 2009; 1(1):31-40. PubMed ID: 20046572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein kinase CK2 protects multiple myeloma cells from ER stress-induced apoptosis and from the cytotoxic effect of HSP90 inhibition through regulation of the unfolded protein response.
    Manni S; Brancalion A; Tubi LQ; Colpo A; Pavan L; Cabrelle A; Ave E; Zaffino F; Di Maira G; Ruzzene M; Adami F; Zambello R; Pitari MR; Tassone P; Pinna LA; Gurrieri C; Semenzato G; Piazza F
    Clin Cancer Res; 2012 Apr; 18(7):1888-900. PubMed ID: 22351691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.
    Pham LV; Tamayo AT; Li C; Bornmann W; Priebe W; Ford RJ
    Mol Cancer Ther; 2010 Jul; 9(7):2026-36. PubMed ID: 20606045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status.
    Pérez-Galán P; Roué G; Villamor N; Montserrat E; Campo E; Colomer D
    Blood; 2006 Jan; 107(1):257-64. PubMed ID: 16166592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities.
    Jung HJ; Chen Z; Wang M; Fayad L; Romaguera J; Kwak LW; McCarty N
    Blood; 2012 Mar; 119(11):2568-78. PubMed ID: 22294726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
    Sydor JR; Normant E; Pien CS; Porter JR; Ge J; Grenier L; Pak RH; Ali JA; Dembski MS; Hudak J; Patterson J; Penders C; Pink M; Read MA; Sang J; Woodward C; Zhang Y; Grayzel DS; Wright J; Barrett JA; Palombella VJ; Adams J; Tong JK
    Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17408-13. PubMed ID: 17090671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.